QM · rank #9 · 2026-09-08
SNT
GPW · PLN · $761M (USD)
The exact numbers the algorithm saw.
| Momentum 12-1 Return from 12 months ago to 1 month ago. | +79.46% |
|---|---|
| ROE TTM Return on equity, trailing 12 months. | +55.1% |
| Profit margin Net profit margin, trailing 12 months. | +16.1% |
| Market cap (USD) Size filter: > $300M required (USD-equivalent). | $761M |
| Anchor (recent) Close on 2026-08-07 | $359.00 |
| Anchor (far) Close on 2025-08-08 | $200.05 |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik S.A. is a Polish healthcare technology provider that produces oncology radiopharmaceuticals and distributes advanced medical imaging equipment and robotic surgery platforms.
Rationale
A stellar 55% ROE and 16% profit margin back up the strong 79.5% price momentum, driven by a 52% YoY revenue surge in FY2025/26 and secured pipeline contracts under Poland's national digital-health program.
Material risks
- 1Revenue is highly vulnerable to public tender cycles and policy shifts due to dependence on Polish public hospitals and EU-funded KPO/e-Zdrowie programs.
- 2Margins could erode if hospital nuclear-medicine labs or competitors successfully expand in-house PET radiotracer production capabilities in Poland.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.